In this work, three IVIGs that showed significantly different therapeutic effects (IVIG-A/B/C) for AD in our previous study were selected to detect and compare the concentrations of specific antibodies to different conformations of soluble Aβ42, tau, and p-tau. This evidence concerns the gene MAPT and Alzheimer disease.